BRAF and melanoma: In support, the Noxa protein levels in BRAFV600E melanoma cells treated with PLX4720 in the presence of the proteasome inhibitor MG132 remained significantly lower compared to those without exposure to the BRAF inhibitor (Figure 2D) [35].